chronic stable angina
unstable angina & high risk features
rest angina
new onset angina
increasing angina
high risk symptoms
rest angina
angina occurring at rest & usually lasting >20min
new onset angina
angina of class III (marked limitation of normal activity) in the past 2 months
increasing angina
stable angina that is now increasing in duration or frequency
high risk symptoms
pulmonary edema
rales
angina w/ hypotension
nocturnal angina
chronic stable angina goals of therapy
chronic stable angina & HTN
non-pharmacological management of chronic stable angina
Can you titrate anti-anginal/BP medications below the standard target BP (e.g,. 140/90) to reduce symptoms of chronic stable angina?
yes
CSA 4 main agents used
beta-blockers, CCB. nitrates & ranolazine
wht therapy may be adequate for symptoms that occur rarely or predictably
PRN nitrates
chronic antianginal therapy should be up-titrated if patients
experience daily episode or symptoms sig. impact QOL
majority of CSA therapy
decreased HR and/or BP
minimal HR
55bpm
minimal BP
100/65
critical side effects
orthostatic hypotension, +/-falls, syncope, severe fatigue
Which pharmacological effects would be helpful in reducing anginal episodes?
○ Beta-blocker to reduce inotropy, thereby reducing cardiac oxygen demand
○ Beta-blocker to reduce chronotropy, thereby reducing cardiac oxygen demand
○ DHP-CCB/nitrate to cause vasodilation, thereby increasing coronary blood flow
○ DHP-CCB/nitrate to cause vasodilation, thereby reducing afterload and cardiac workload
first line in the management of CSA
beta blockers
beta-1 selective
mixed alpha/beta blockers
(Carvedilol)
- may be used if additional BP control is needed
agents with intrinsic sympathomimetic activity
should be avoided
- increase HR
beta blocker dosing
titrate BB to HR of ~55bpm as BP & side effects allow
- add additional agents as necessary
BB in combo with nonDHP CCBs
avoided due to risk of bradycardia & Heart block